<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38424537</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1744-859X</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>29</Day></PubDate></JournalIssue><Title>Annals of general psychiatry</Title><ISOAbbreviation>Ann Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.</ArticleTitle><Pagination><StartPage>10</StartPage><MedlinePgn>10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12991-024-00494-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Post-COVID-19 Condition (PCC), as defined by the World Health Organization (WHO), currently lacks any regulatory-approved treatments and is characterized by persistent and debilitating cognitive impairment and mood symptoms. Additionally, metabolic dysfunction, chronic inflammation and the associated risks of elevated body mass index (BMI) have been reported. In this study, we aim to investigate the efficacy of vortioxetine in improving cognitive deficits in individuals with PCC, accounting for the interaction of metabolic dysfunction, elevated inflammation and BMI.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a post-hoc analysis of an 8-week randomized, double-blind, placebo-controlled trial that was conducted among adults aged 18 years and older living in Canada who were experiencing WHO-defined PCC symptoms. The recruitment of participants began in November 2021 and concluded in January 2023. A total of 200 individuals were enrolled, where 147 were randomized in a 1:1 ratio to receive either vortioxetine (5-20 mg, n&#x2009;=&#x2009;73) or placebo (n&#x2009;=&#x2009;74) for daily treatment under double-blind conditions. The primary outcome measure was the change in the Digit Symbol Substitution Test (DSST) score from baseline to endpoint.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our findings showed significant effects for time (&#x3c7;<sup>2</sup>&#x2009;=&#x2009;7.771, p&#x2009;=&#x2009;0.005), treatment (&#x3c7;<sup>2</sup>&#x2009;=&#x2009;7.583, p&#x2009;=&#x2009;0.006) and the treatment x time x CRP x TG-HDL x BMI interaction (&#x3c7;<sup>2</sup>&#x2009;=&#x2009;11.967, p&#x2009;=&#x2009;0.018) on cognitive function. Moreover, the between-group analysis showed a significant improvement with vortioxetine at endpoint (mean difference&#x2009;=&#x2009;0.621, SEM&#x2009;=&#x2009;0.313, p&#x2009;=&#x2009;0.047).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, vortioxetine demonstrated significant improvements in cognitive deficits among individuals with baseline markers of metabolic dysfunction, elevated inflammation and higher BMI at endpoint as compared to placebo.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT05047952 (ClinicalTrials.gov; Registration Date: September 17, 2021).</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwan</LastName><ForeName>Angela T H</ForeName><Initials>ATH</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le</LastName><ForeName>Gia Han</ForeName><Initials>GH</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Ziji</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ceban</LastName><ForeName>Felicia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teopiz</LastName><ForeName>Kayla M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Taeho Greg</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health Sciences, University of Connecticut School of Medicine, Storrs, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Vincenzo</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badulescu</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meshkat</LastName><ForeName>Shakila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing, 400715, P. R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenblat</LastName><ForeName>Joshua D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dev</LastName><ForeName>Donovan A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniapillai</LastName><ForeName>Mehala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Brain and Cognition Discovery Foundation, 77 Bloor Street West, Suite 617, Toronto, ON, M5S 1M2, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada. roger.mcintyre@bcdf.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05047952</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Gen Psychiatry</MedlineTA><NlmUniqueID>101236515</NlmUniqueID><ISSNLinking>1744-859X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Body mass index (BMI)</Keyword><Keyword MajorTopicYN="N">Cognitive function</Keyword><Keyword MajorTopicYN="N">Digit symbol substitution test (DSST)</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Metabolic dysfunction</Keyword><Keyword MajorTopicYN="N">Vortioxetine</Keyword></KeywordList><CoiStatement>Dr. Roger S. McIntyre has received research grant support from CIHR, GACD, National Natural Science Foundation of China (NSFC), and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp.Felicia Ceban, Kayla M. Teopiz and Mehala Subramaniapillai have received fees from Braxia Scientific Corp.Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (NIA) (#R21AG070666; R21AG078972), National Institute of Mental Health (#R21MH117438), National Institute on Drug Abuse (#R21DA057540) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP) of the University of Connecticut. Dr. Rhee serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for International Alliance of Mental Health Research Funders (IAMHRF). Dr. Rhee is currently a co-Editor-in-Chief of Mental Health Science and has received honorarium payments annually from the publisher, John Wiley &amp; Sons, Inc. Dr. Roger Ho has received funding from the National University of Singapore iHeathtech Other Operating Expenses (A-0001415-09-00).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>1</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>1</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>29</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38424537</ArticleId><ArticleId IdType="pmc">PMC10905871</ArticleId><ArticleId IdType="doi">10.1186/s12991-024-00494-1</ArticleId><ArticleId IdType="pii">10.1186/s12991-024-00494-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus disease (COVID-19) dashboard. COVID 19 Special Issue [Internet]. 2020;10(1). Available from: https://covid19.who.int/.</Citation></Reference><Reference><Citation>Post COVID-. 19 condition [Internet]. [cited 2023 Sep 12]. Available from: https://www.who.int/teams/health-care-readiness/post-covid-19-condition.</Citation></Reference><Reference><Citation>Mahase E. Covid-19: what do we know about long covid? BMJ. 2020;370:m2815. doi: 10.1136/bmj.m2815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m2815</ArticleId><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz Neto J, Frota Cavalcante T, de Carvalho F&#xe9;lix ND. Post-COVID-19 metabolic syndrome: a new challenge for nursing care. Invest Educ Enferm [Internet]. 2023;41(1). 10.17533/udea.iee.v41n1e01.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10152914</ArticleId><ArticleId IdType="pubmed">37071858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacavalerie MR, Pierre-Francois S, Agossou M, Inamo J, Cabie A, Barnay JL, et al. Obese patients with long COVID-19 display abnormal hyperventilatory response and impaired gas exchange at peak exercise. Future Cardiol. 2022;18(7):577&#x2013;84. doi: 10.2217/fca-2022-0017.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fca-2022-0017</ArticleId><ArticleId IdType="pmc">PMC9169685</ArticleId><ArticleId IdType="pubmed">35658540</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Guti&#xe9;rrez S, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin. 2022;38(6):901&#x2013;9. doi: 10.1080/03007995.2022.2042991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2022.2042991</ArticleId><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan M, Wang X, Gong M, Wang Q, Li Y, Jia J. Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg Health West Pac. 2023;38:100836. doi: 10.1016/j.lanwpc.2023.100836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100836</ArticleId><ArticleId IdType="pmc">PMC10344681</ArticleId><ArticleId IdType="pubmed">37457901</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265&#x2013;73. doi: 10.1001/jamacardio.2020.3557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.3557</ArticleId><ArticleId IdType="pmc">PMC7385689</ArticleId><ArticleId IdType="pubmed">32730619</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787&#x2013;94. doi: 10.1016/j.jad.2017.11.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2017.11.081</ArticleId><ArticleId IdType="pubmed">29689693</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018;175(1):113&#x2013;24. doi: 10.1111/bph.14074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14074</ArticleId><ArticleId IdType="pmc">PMC5740236</ArticleId><ArticleId IdType="pubmed">29057467</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry. 2018;23(5):1127&#x2013;33. doi: 10.1038/mp.2017.104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2017.104</ArticleId><ArticleId IdType="pmc">PMC5984095</ArticleId><ArticleId IdType="pubmed">28533517</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol [Internet]. 2016;19(10). 10.1093/ijnp/pyw055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091829</ArticleId><ArticleId IdType="pubmed">27312740</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CS, Carvalho AF, McIntyre RS. Towards a metabolic subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693&#x2013;707. doi: 10.2174/1871527313666141130204031.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527313666141130204031</ArticleId><ArticleId IdType="pubmed">25470395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#x2013;97. doi: 10.1038/nri2921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2921</ArticleId><ArticleId IdType="pmc">PMC3518031</ArticleId><ArticleId IdType="pubmed">21252989</ArticleId></ArticleIdList></Reference><Reference><Citation>Samant P, Chavan P, Rai S. TG/HDL-C ratio: a surrogate marker of insulin resistance in patients with metabolic syndrome. MGM J Med Sci. 2014;1(1):18&#x2013;21. doi: 10.5005/jp-journals-10036-1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.5005/jp-journals-10036-1004</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS. Surrogate markers of insulin resistance in Predicting Major Depressive Disorder: metabolism metastasizes to the brain. Am J Psychiatry. 2021;178(10):885&#x2013;7. doi: 10.1176/appi.ajp.2021.21080814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2021.21080814</ArticleId><ArticleId IdType="pubmed">34592845</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson KT, Simard JF, Henderson VW, Nutkiewicz L, Lamers F, Nasca C, et al. Incident Major Depressive Disorder predicted by three measures of insulin resistance: a Dutch cohort study. Am J Psychiatry. 2021;178(10):914&#x2013;20. doi: 10.1176/appi.ajp.2021.20101479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2021.20101479</ArticleId><ArticleId IdType="pubmed">34551583</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Nogo D, Carvalho IP, Lee Y, Nasri F, Xiong J, et al. Association between Mood disorders and Risk of COVID-19 infection, hospitalization, and death: a systematic review and Meta-analysis. JAMA Psychiatry. 2021;78(10):1079&#x2013;91. doi: 10.1001/jamapsychiatry.2021.1818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2021.1818</ArticleId><ArticleId IdType="pmc">PMC8319830</ArticleId><ArticleId IdType="pubmed">34319365</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Phan L, Kwan ATH, Mansur RB, Rosenblat JD, Guo Z, et al. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain [Internet]. 2023 Nov 4. 10.1093/brain/awad377</Citation><ArticleIdList><ArticleId IdType="pubmed">37936330</ArticleId></ArticleIdList></Reference><Reference><Citation>Makhoul E, Aklinski JL, Miller J, Leonard C, Backer S, Kahar P, et al. A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and Dyslipidemia. Cureus. 2022;14(7):e27438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9420458</ArticleId><ArticleId IdType="pubmed">36051728</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;95e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein SR, Cozma D, Kamel M, Hamad M, Mohammad MG, Khan NA, et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res. 2022;54(8):562&#x2013;6. doi: 10.1055/a-1878-9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1878-9307</ArticleId><ArticleId IdType="pmc">PMC9363148</ArticleId><ArticleId IdType="pubmed">35724687</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansur RB, Brietzke E, McIntyre RS. Is there a metabolic-mood syndrome? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015;52:89&#x2013;104. doi: 10.1016/j.neubiorev.2014.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2014.12.017</ArticleId><ArticleId IdType="pubmed">25579847</ArticleId></ArticleIdList></Reference><Reference><Citation>Soczynska JK, Kennedy SH, Woldeyohannes HO, Liauw SS, Alsuwaidan M, Yim CY, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13(2):93&#x2013;116. doi: 10.1007/s12017-010-8140-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-010-8140-8</ArticleId><ArticleId IdType="pubmed">21165712</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblat JD, McIntyre RS. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand. 2015;132(3):180&#x2013;91. doi: 10.1111/acps.12414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acps.12414</ArticleId><ArticleId IdType="pubmed">25772638</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen JCD, Killcross AS, Jenkins TA. Obesity and cognitive decline: role of inflammation and vascular changes. Front Neurosci. 2014;8:375. doi: 10.3389/fnins.2014.00375.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2014.00375</ArticleId><ArticleId IdType="pmc">PMC4237034</ArticleId><ArticleId IdType="pubmed">25477778</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Torres-Macho J, Elvira-Mart&#xed;nez CM, Molina-Trigueros LJ, Sebasti&#xe1;n-Viana T, Hern&#xe1;ndez-Barrera V. Obesity is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: a multicentre case-control study. Int J Clin Pract. 2021;75(12):e14917. doi: 10.1111/ijcp.14917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14917</ArticleId><ArticleId IdType="pmc">PMC8646300</ArticleId><ArticleId IdType="pubmed">34569684</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen A, Bressem K, Albrecht J, Thie&#xdf; HM, Vahldiek J, Hamm B, et al. The role of visceral adiposity in the severity of COVID-19: highlights from a unicenter cross-sectional pilot study in Germany. Metabolism. 2020;110:154317. doi: 10.1016/j.metabol.2020.154317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154317</ArticleId><ArticleId IdType="pmc">PMC7358176</ArticleId><ArticleId IdType="pubmed">32673651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16(12):1017&#x2013;29. doi: 10.1111/obr.12320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.12320</ArticleId><ArticleId IdType="pubmed">26354800</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69(1):29&#x2013;35. doi: 10.1016/j.diabres.2004.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2004.11.007</ArticleId><ArticleId IdType="pubmed">15955385</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm [Internet]. 2010;2010. 10.1155/2010/289645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2913796</ArticleId><ArticleId IdType="pubmed">20706689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitzbichler MG, Aruldass AR, Barker GJ, Wood TC, Dowell NG, Hurley SA, et al. Peripheral inflammation is associated with micro-structural and functional connectivity changes in depression-related brain networks. Mol Psychiatry. 2021;26(12):7346&#x2013;54. doi: 10.1038/s41380-021-01272-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01272-1</ArticleId><ArticleId IdType="pmc">PMC8872995</ArticleId><ArticleId IdType="pubmed">34535766</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte JMN. Metabolic alterations Associated to Brain Dysfunction in Diabetes. Aging Dis. 2015;6(5):304&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4567214</ArticleId><ArticleId IdType="pubmed">26425386</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordestani-Moghadam P, Assari S, Nouriyengejeh S, Mohammadipour F, Pourabbasi A. Cognitive impairments and Associated Structural Brain changes in metabolic syndrome and implications of neurocognitive intervention. J Obes Metab Syndr. 2020;29(3):174&#x2013;9. doi: 10.7570/jomes20021.</Citation><ArticleIdList><ArticleId IdType="doi">10.7570/jomes20021</ArticleId><ArticleId IdType="pmc">PMC7539347</ArticleId><ArticleId IdType="pubmed">32747611</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakahachi T, Ishii R, Iwase M, Canuet L, Takahashi H, Kurimoto R, et al. Frontal activity during the digit symbol substitution test determined by multichannel near-infrared spectroscopy. Neuropsychobiology. 2008;57(4):151&#x2013;8. doi: 10.1159/000147467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000147467</ArticleId><ArticleId IdType="pubmed">18654084</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>